Santero Therapeutics seeks to provide novel medications with fresh modes of action that combat diseases with high resistance.
Santero Therapeutics has raised $8.6M in total funding. The most recent round was Series A. The last funding was announced in June 2023.
Santero Therapeutics's investors include Newton Biocapital, SFPIM, Sambrinvest, S.R.I.W., Pierre Drion.
Santero Therapeutics is headquartered in Charleroi, Belgium.
Santero Therapeutics seeks to provide novel medications with fresh modes of action that combat diseases with high resistance.
Santero Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Santero Therapeutics — Funding & Investors." VCBacked, June 7, 2023, https://www.vcbacked.co/company/santero-therapeutics. Accessed September 30, 2026.
VCBacked. (2023). Santero Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/santero-therapeutics
{{cite web |title=Santero Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/santero-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated